Cancer Related Cognitive Impairment
NCT03949322, Not applicable, Unknown, Institut Cancerologie de l'Ouest
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Cancer Related Cognitive Impairment | ClinicalTrials.gov |
| NCT number | NCT03949322 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 26 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Institut Cancerologie de l'Ouest | ClinicalTrials.gov |
| Conditions | Patients Treated for Cancer | ClinicalTrials.gov |
| Interventions | Adapted Physical Activity Program | ClinicalTrials.gov |
| First posted | 2019-05-14 | ClinicalTrials.gov |
| Last updated | 2019-05-14 | ClinicalTrials.gov |
Registered outcomes 9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Effect of an APA program on cognitive functions (inhibition) | 8 weeks | For inhibition, effect of APA program on cognitive functions is evaluated with Stroop task. | ClinicalTrials.gov |
| Primary | Effect of an APA program on cognitive functions (speed function of information processing) | 8 weeks | For speed function of information processing, effect of APA program on cognitive functions is evaluated with XO letters comparison test. During the XO letters comparison test, the participants will have to check the maximum number of identical or different boxes according to the combination of the two letters presented (XO, OX, XX or OO) in 30 seconds. | ClinicalTrials.gov |
| Primary | Effect of an APA program on cognitive functions (Episodic Memory Function) | 8 weeks | For Episodic Memory Function, effect of APA program on cognitive functions is evaluated with MEM III test. | ClinicalTrials.gov |
| Secondary | To determine if the APA program modifies PA (Physical Activity) patterns in daily life | 8 weeks | Evaluated with Global Physical Activity Questionnaire | ClinicalTrials.gov |
| Secondary | To determine if the APA program modifies PA (Physical Activity) patterns in daily life | 8 weeks | Evaluated with Actimeter | ClinicalTrials.gov |
| Secondary | Determine which PA pattern is the best predictor of cognitive performance improvement following the APA program, , by controlling the effect of cognitive risk factors. | 8 weeks | Level of overall cognitive abilities: Montreal Cognitive Assessment (MOCA) | ClinicalTrials.gov |
| Secondary | Determine which PA pattern is the best predictor of cognitive performance improvement following the APA program, , by controlling the effect of cognitive risk factors. | 8 weeks | Level of education: questionnaire measuring the number of years of study | ClinicalTrials.gov |
| Secondary | Determine which PA pattern is the best predictor of cognitive performance improvement following the APA program, , by controlling the effect of cognitive risk factors. | 8 weeks | Level of Anxiety and Depression: Hospital and Anxiety Depression Scale (HADS). | ClinicalTrials.gov |
| Secondary | Determine which PA pattern is the best predictor of cognitive performance improvement following the APA program, , by controlling the effect of cognitive risk factors. | 8 weeks | Fatigue level: Multidimensional Fatigue Inventor (MFI) | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)